Monoclonal Antibody Therapies for Traumatic Brain Injury
Author Information
Author(s): Wang Ping, Okada-Rising Starlyn, Scultetus Anke H., Bailey Zachary S.
Primary Institution: Walter Reed Army Institute of Research
Hypothesis
Can monoclonal antibody therapies mitigate secondary injury cascades following traumatic brain injury?
Conclusion
Monoclonal antibody therapies have the potential to target and mitigate the complex pathological processes associated with traumatic brain injury.
Supporting Evidence
- Traumatic brain injury is a leading cause of morbidity and mortality worldwide.
- Monoclonal antibodies can target specific pathways involved in the secondary injury cascades after TBI.
- Current therapeutic interventions for TBI are limited and often target single factors.
Takeaway
This study looks at how special medicines called monoclonal antibodies might help people who have hurt their brains. They can help fix problems that happen after the injury.
Methodology
The authors reviewed publicly available databases to assess the relevance of monoclonal antibody therapies to traumatic brain injury pathology.
Limitations
The review highlights the lack of studies evaluating monoclonal antibody potential within traumatic brain injury pathology.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website